Management's own description of their firm: Alaunus Biosciences is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need.
